At Axleres Biosciences, we bring together cutting-edge AI/ML algorithms, physics-based modeling, and domain expertise to accelerate discovery and development across modalities .
Our in-silico and computational capabilities enable faster decision-making, smarter candidate selection, and reduced experimental rework across the discovery and development continuum.
Ultra-scale virtual screening of up to multi trillion molecules
Generative AI/ML for de novo design, scaffold hopping, and molecular novelty
AI-powered property prediction for early prioritization
ML-assisted SAR modeling and multi-parameter optimization
Advanced Free Energy Perturbation (FEP) for accurate binding affinity predictions — effective for peptides, macrocycles, covalent inhibitors, and more
In silico ADMET, PBPK, and DMPK profiling to minimize downstream attrition
Generative AI for retrosynthesis planning, impurity prediction, and process chemistry feasibility
AI-assisted impurity fate and purge prediction
AI-based formulation design, excipient compatibility, and drug–drug/excipient interaction prediction
Stability modeling to support preclinical and clinical formulation strategies
Accurate in silico methods for ligand crystal structure prediction, including free base, salt, hydrate, and co-crystal forms
Tools to assess polymorphic risk early on and guide solid-form selection
Whether you're in early-stage screening or late-stage optimization, our AI/ML and in-silico offerings act as your Digital Companion— increasing confidence, compressing timelines, and making your science more predictable.